RMC No. 125-2022: Updated FDA List Deletes Certain COVID-19 Treatment Medicines from CREATE Act VAT Exemption

RMC No. 125-2022 updates the FDA VAT-exempt medicines list, deleting certain COVID-19 treatment medicines under the CREATE Act. Businesses selling, purchasing, importing, distributing, prescribing, or accounting for medicines used in COVID-19 treatment must immediately re-check the current FDA-published List of VAT-Exempt Medicines before treating those medicines as VAT-exempt. RMC No. 125-2022 makes a critical update […]

RMC No. 110-2022: VAT Exemption Updates for Certain Cancer and COVID-19 Medicines Under the CREATE Act

RMC No. 110-2022 updates VAT-exempt medicines under CREATE, covering certain cancer and COVID-19 medicines effective upon FDA publication. Businesses selling, purchasing, importing, prescribing, or accounting for medicines used in cancer and COVID-19 treatment must verify whether the specific medicines they handle are now included in the updated List of VAT-Exempt Medicines. RMC No. 110-2022 matters […]